Dr. Raghu Satyanarayan is an eminent Consulting Physician from Ahmedabad in Gujarat and is associated with Sterling Hospital. He is also a member of IMA, APA and RSSDI.
GLP-1 inhibitors are the class of molecules utilized for the treatment of T2DM. It works by activating GLP-1 receptor and is generally more potent in Hb1AC control, hypoglycemic variability and in patients with atherosclerotic cardiovascular disease as an added advantage.
This exclusive commentary briefs on the highlighting features of SGLP-1 inhibitors in the treatment of T2DM.
